Literature DB >> 25729643

Genomic analysis to define molecular basis of aggressiveness in a mouse model of oral cancer.

Varun Chalivendra1, Krishna Latha Kanchi1, Michael D Onken1, Ashley E Winkler1, Elaine Mardis1, Ravindra Uppaluri1.   

Abstract

To investigate the molecular basis underlying aggressive behavior in oral squamous cell carcinoma (OSCC), our laboratory developed a carcinogen-induced mouse oral cancer (MOC) cell line model that encompasses the growth and metastasis spectrum of its human counterpart. We performed next-generation sequencing (NGS) and gene expression microarray profiles to explore the genomic and transcriptional backgrounds of the differential MOC line phenotypes, as well as, the cross-species relevance of the model. Here we describe the comparative analysis of NGS (www.ncbi.nlm.nih.gov/biosample?LinkName=bioproject_biosample_all&from_uid=247825) and expression microarray (www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50041) data from the MOC lines and corresponding human data, as described in our recent publication [1].

Entities:  

Year:  2015        PMID: 25729643      PMCID: PMC4340082          DOI: 10.1016/j.gdata.2014.11.006

Source DB:  PubMed          Journal:  Genom Data        ISSN: 2213-5960


Specifications

NGS to determine mutational landscape of mouse oral cancer lines Microarray to determine transcriptional landscape of mouse oral cancer lines Comparative analysis of genomic and transcriptional data between aggressive and indolent mouse oral cancer lines Comparative analysis between mouse model and published human sequencing and microarray data

Direct link to deposited data

NGS: www.ncbi.nlm.nih.gov/biosample?LinkName=bioproject_biosample_all&from_uid=247825 Microarray: www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50041

Experimental design, materials and methods

Cell lines

We have previously described a 7,12 dimethylbenzanthracene (DMBA)-induced mouse cell line model of OSCC where individual lines display fixed in vivo phenotypes [2]. We classified these lines into indolent or aggressive subtypes based on their in vivo growth patterns in syngeneic mice. Indolent lines formed primary tumors at orthotopic and heterotopic injection sites but did not display evidence of metastasis. By contrast the aggressive lines all displayed regional lymph node as well as occasional lung metastases. Further genotyping analysis revealed that the three aggressive lines were related with MOC2-7 and MOC2-10 being derived from the MOC2 line.

Sequencing

MOC lines were grown in defined media and used for genomic DNA preparation, while CXCR3−/− DNA was generated from mouse splenocytes (Qiagen DNeasy Blood & Tissue Kit). NGS was performed at The Genome Institute at Washington University School of Medicine with their standard platforms and resulted in excellent depth of coverage. A critical point in the analysis was due to the lack of control tissue available from the original mice bearing the parental tumors. Thus, mutation reads were normalized to the reference C57BL/6 genome and a genomic database of 17 commonly used strains of inbred laboratory mice. Human mutational data from all oral squamous cell carcinoma (OSCC) cases were acquired from published data, The Cancer Genome Atlas (TCGA), The Broad Institute platform, and from cBioPortal (http://www.cbioportal.org/public-portal/).

Sequencing quality control and analysis

Analysis of sequencing data is described in detail in our publication [1]. We excluded the common and well-known variants using the dbSNP filter, and the novel variants were manually reviewed to decrease the false discovery rate. With the goal of further understanding the signatures of metastasis and identifying immune targets, we performed Varscan copy number analysis and recurrent gene analysis. We also performed clonality analysis using the point mutations to reveal the subclonal architecture within the cell lines. Growth phenotype-specific mutations, and comparative analysis between aggressive versus indolent MOC lines, and lymph node metastasis negative versus lymph node positive TCGA OSCC samples, were established in Microsoft Excel using IF and VLOOKUP commands. The prevalence of specific mutations in human OSCC cases from TCGA was determined using cBioPortal.

Microarray

Primary oral keratinocytes were generated by harvesting oral mucosa from C57BL/6 mice. The mucosa was digested overnight in Dispase (Roche) and epithelial layers were then microdissected. Epithelium was then briefly digested with trypsin (HyClone) and single cell suspensions were generated. These cells were then grown in specialized media (CellNTec) until near confluent cultures were obtained. Cells were subsequently grown for 24 h in MOC cell line media. Total RNA was generated from 3 to 4 independent cultures of MOC lines and two independent cultures of primary oral keratinocytes using the RNeasy Kit (Qiagen). RNA quality was assessed using Agilent Nano Chips and samples with RNA integrity values of 8–10 were subsequently submitted for gene expression profiling using Illumina MouseRef-8 Expression BeadChips. Raw expression data were normalized using the cubic spline method in Genome-Studio 2011.1. Human OSCC expression data were acquired from four independent published databases (UW/FHCRC, MD Anderson [3], University of Pennsylvania [4] and TCGA). Only proven human papilloma virus negative cases were included. Tumor stage or regional lymph node metastasis status were used to categorize aggressive versus indolent cases.

Microarray analysis

The normalized expression data were imported into Partek Genomics Suite 6.6. Further analysis is described in our recent publication and resulted in the identification of gene sets representing a mouse signature of aggressiveness [1]. Iterative and tandem gene set enrichment analysis (GSEA) was used to find overlap of the mouse signature genes in three human datasets, and to eliminate mouse-specific transcripts. This process trimmed the number of cross-species relevant transcripts to 188 genes.

Discussion

We describe here our two-fold genomic approach, of exome sequencing and expression microarray, to expose mutational and transcriptional alterations and to delineate the genetic basis of aggressive growth in our murine OSCC model. By performing a comparative analysis with human genomic and gene expression data, we found (1) overlap with the most commonly mutated genes in human HNSCC, (2) new potential driver mutations, (3) novel candidate genes with transcriptional changes associated with aggressive growth, and (4) a cross-species conserved 118-gene signature predictive of aggressive disease and metastasis in OSCC. These data support the use of carcinogen-induced mouse oral cancer cell lines as a high-fidelity model of the human counterpart.

Conflict of interest

The authors have no conflicts of interest.
Specifications
Organism/cell line/tissueMus musculus
SexN/A
Sequencer or array typeNGS: Illumina HiSeq2000Microarray: Illumina MouseRef-8
Data formatNGS: raw data in SRA filesMicroarray: raw data in TXT files
Experimental factorsNGS: mouse oral squamous cell carcinoma cell linesMicroarray: mouse oral squamous cell carcinoma cell lines, metastatic lymph node, control primary C57BL/6 splenocytes
Experimental features

NGS to determine mutational landscape of mouse oral cancer lines

Microarray to determine transcriptional landscape of mouse oral cancer lines

Comparative analysis of genomic and transcriptional data between aggressive and indolent mouse oral cancer lines

Comparative analysis between mouse model and published human sequencing and microarray data

ConsentN/A
Sample source locationSaint Louis, MO, United States
  4 in total

1.  ERK1/2 regulation of CD44 modulates oral cancer aggressiveness.

Authors:  Nancy P Judd; Ashley E Winkler; Oihana Murillo-Sauca; Joshua J Brotman; Jonathan H Law; James S Lewis; Gavin P Dunn; Jack D Bui; John B Sunwoo; Ravindra Uppaluri
Journal:  Cancer Res       Date:  2011-11-15       Impact factor: 12.701

2.  Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity.

Authors:  Rebekah K O'Donnell; Michael Kupferman; S Jack Wei; Sunil Singhal; Randal Weber; Bert O'Malley; Yi Cheng; Mary Putt; Michael Feldman; Barry Ziober; Ruth J Muschel
Journal:  Oncogene       Date:  2005-02-10       Impact factor: 9.867

3.  Gene expression in uninvolved oral mucosa of OSCC patients facilitates identification of markers predictive of OSCC outcomes.

Authors:  Pawadee Lohavanichbutr; John Houck; David R Doody; Pei Wang; Eduardo Mendez; Neal Futran; Melissa P Upton; F Christopher Holsinger; Stephen M Schwartz; Chu Chen
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

4.  A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease.

Authors:  Michael D Onken; Ashley E Winkler; Krishna-Latha Kanchi; Varun Chalivendra; Jonathan H Law; Charles G Rickert; Dorina Kallogjeri; Nancy P Judd; Gavin P Dunn; Jay F Piccirillo; James S Lewis; Elaine R Mardis; Ravindra Uppaluri
Journal:  Clin Cancer Res       Date:  2014-03-25       Impact factor: 12.531

  4 in total
  6 in total

Review 1.  Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.

Authors:  Y S Tan; K Sansanaphongpricha; M E P Prince; D Sun; G T Wolf; Y L Lei
Journal:  J Dent Res       Date:  2018-03-13       Impact factor: 6.116

Review 2.  The mouse oral carcinoma (MOC) model: A 10-year retrospective on model development and head and neck cancer investigations.

Authors:  Michihisa Kono; Shin Saito; Ann Marie Egloff; Clint T Allen; Ravindra Uppaluri
Journal:  Oral Oncol       Date:  2022-07-09       Impact factor: 5.972

Review 3.  Head and Neck Cancer Stem Cells: From Identification to Tumor Immune Network.

Authors:  L K Dionne; E R Driver; X J Wang
Journal:  J Dent Res       Date:  2015-08-07       Impact factor: 6.116

4.  Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4.

Authors:  Zhiyong Wang; Victoria H Wu; Michael M Allevato; Mara Gilardi; Yudou He; Juan Luis Callejas-Valera; Lynn Vitale-Cross; Daniel Martin; Panomwat Amornphimoltham; James Mcdermott; Bryan S Yung; Yusuke Goto; Alfredo A Molinolo; Andrew B Sharabi; Ezra E W Cohen; Qianming Chen; J Guy Lyons; Ludmil B Alexandrov; J Silvio Gutkind
Journal:  Nat Commun       Date:  2019-12-05       Impact factor: 14.919

5.  Tumor-associated neutrophils (TANs) in human carcinoma-draining lymph nodes: a novel TAN compartment.

Authors:  Silvia Lonardi; Francesco Missale; Stefano Calza; Mattia Bugatti; Raffaella Vescovi; Bresciani Debora; Ravindra Uppaluri; Ann Marie Egloff; Davide Mattavelli; Davide Lombardi; Luisa Benerini Gatta; Olivia Marini; Nicola Tamassia; Elisa Gardiman; Marco A Cassatella; Patrizia Scapini; Piero Nicolai; William Vermi
Journal:  Clin Transl Immunology       Date:  2021-02-16

6.  Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.

Authors:  Aurelie Hanoteau; Jared M Newton; Rosemarie Krupar; Chen Huang; Hsuan-Chen Liu; Angelina Gaspero; Robyn D Gartrell; Yvonne M Saenger; Thomas D Hart; Saskia J Santegoets; Damya Laoui; Chad Spanos; Falguni Parikh; Padmini Jayaraman; Bing Zhang; Sjoerd H Van der Burg; Jo A Van Ginderachter; Cornelis J M Melief; Andrew G Sikora
Journal:  J Immunother Cancer       Date:  2019-01-15       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.